☰

Douglas B. Muchmore, MD

Affiliations: 
Vice President, Endocrinology Clinical Development. Halozyme Therapeutics, Inc, San Diego, CA, United States 
Area:
Cell biology
Website:
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1199823&highlight=
Google:
"Douglas Muchmore"
Bio:

Undergraduate student in the lab of David Epel.

http://www.activetransporter.com/2010/10

http://salesandmarketingnetwork.com/news_release.php?pipe=0000ac177000191&ID=2026113

Mean distance: 106866 (cluster 28)
 		SNBCP
Cross-listing: Cell Biology Tree

Tree Publications Grants Similar researchers PubMed Report error

Parents

Sign in to add mentor
David Epel research assistant Stanford

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Tian T, Aaron RE, DuNova AY, et al. (2024) Diabetes Technology Meeting 2023. Journal of Diabetes Science and Technology. 19322968241235205
Aaron RE, Tian T, Yeung AM, et al. (2023) NIH Fifth Artificial Pancreas Workshop 2023: Meeting Report: The Fifth Artificial Pancreas Workshop: Enabling Fully Automation, Access, and Adoption. Journal of Diabetes Science and Technology. 19322968231201829
Kastner JR, Bailey TS, Strange P, et al. (2022) PROGRESSIVE ACCELERATION OF INSULIN EXPOSURE OVER SEVEN DAYS OF INFUSION SET WEAR. Diabetes Technology & Therapeutics
Muchmore DB. (2022) Regarding: Insulin Infusion Set Failures. Diabetes Technology & Therapeutics. 24: 599-600
Weinstock RS, Bode BW, Garg SK, et al. (2022) Reduced hypoglycaemia using liver-targeted insulin in individuals with type 1 diabetes. Diabetes, Obesity & Metabolism
Kastner JR, Venkatesh N, Brown K, et al. (2022) Feasibility study of a prototype extended-wear insulin infusion set in adults with type 1 diabetes. Diabetes, Obesity & Metabolism
Bode BW, Weinstock RS, Garg SK, et al. (2020) 111-LB: Hepatic Insulin Delivery to Minimize Hypoglycemic Events in Persons with Type 1 Diabetes: The OPTI-1 Study Diabetes. 69
Klonoff D, Bode B, Cohen N, et al. (2019) Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes. Diabetes Care
Klonoff DC, Bode BW, Cohen NJ, et al. (2019) 1084-P: Divergent Hypoglycemic Effects of Hepatic Directed Prandial Insulin: A 6-Month Study in Type 1 Diabetes Mellitus (T1DM) Diabetes. 68
Pettis RJ, Muchmore D, Heinemann L. (2018) Subcutaneous Insulin Administration: Sufficient Progress or Ongoing Need? Journal of Diabetes Science and Technology. 13: 3-7
See more...